Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120
about
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIVFailure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV.Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolatePolymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex.Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzeesHuman monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain.Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.Vaccine protection against simian immunodeficiency virus infection.The ethical conduct of clinical trials of HIV vaccines.Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope proteinEnhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines.Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1.The auto-regulation model: a unified concept of how HIV regulates its infectivity, pathogenesis and persistence.HIV-1(89.6) Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in miceVariants selected by treatment of human immunodeficiency virus-infected cells with an immunotoxin.Neutralizing antibodies to HIV-1 induced by immunization.Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primatesGeneration of deletion mutants of simian immunodeficiency virus incapable of proviral integration.Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboonsInduction of high-titer neutralizing antibodies, using hybrid human immunodeficiency virus V3-Ty viruslike particles in a clinically relevant adjuvantIdentification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120Protection of sheep against bovine leukemia virus (BLV) infection by vaccination with recombinant vaccinia viruses expressing BLV envelope glycoproteins: correlation of protection with CD4 T-cell response to gp51 peptide 51-70.Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1.Analysis of a highly immunodominant epitope in the human immunodeficiency virus type 1 transmembrane glycoprotein, gp41, defined by a human monoclonal antibodyAntibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro.Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animalsAntibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzeesOligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1Expression and immunogenicity of the extracellular domain of the human immunodeficiency virus type 1 envelope glycoprotein, gp160.Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.Immunization of chimpanzees confers protection against challenge with human immunodeficiency virusProtection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences.Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitroAnimal models for development of an AIDS vaccine.Adjuvants.Conformational changes affecting the V3 and CD4-binding domains of human immunodeficiency virus type 1 gp120 associated with env processing and with binding of ligands to these sites.Development of an epitope-based HIV-1 vaccine strategy from HIV-1 lipopeptide to dendritic-based vaccines.Structural analysis of the human immunodeficiency virus-binding domain of CD4. Epitope mapping with site-directed mutants and anti-idiotypes.
P2860
Q24531479-7AFE0300-3A13-4869-86A1-6165FF88403DQ33395672-AD4B810D-B3B1-48D6-BABE-5424582B6AECQ33649062-904CFB2C-0129-4589-AF80-882188C1A0CCQ33811940-E0C668F3-0138-44F4-B541-29701A3C1D58Q33822379-E46C1562-0979-44BA-BC67-BEF231666511Q33864057-06182BFB-8C7A-4B6D-9652-52F75EA7CAFAQ33880904-A62A42C7-E17F-4B23-B6F1-E89E93A3B1C2Q33898692-4E0930AF-3D63-4C19-950E-9C8B424B29B7Q34298187-ABBEC74D-0477-49EE-9A46-EA34BCCB7964Q34412044-A9F1B35B-F1B4-495C-A18F-0EA00633CE7FQ34787140-DEF5C812-8687-4D04-84C4-AEA1EE3A63AAQ35839932-02F553FB-C6C1-4DFE-8843-F2CDE97F9A4CQ35863652-92ECAFBC-1D12-4A6A-8E55-C7B9600D2378Q36055538-8E4159C1-331E-4E62-B237-1752B5DF2A9CQ36156347-A9BD4108-B818-4A87-8605-186B9D147A89Q36353458-A0138306-5E62-457D-9DDC-F445EF56F989Q36603515-6EB893D8-DA07-429C-B494-E9D8CD601B07Q36624976-3432268C-5637-4533-89CB-35233F1DC461Q36655941-693E0916-95B1-4526-A0DA-9333D91BD187Q36655953-F3CFBE20-7416-4D5C-9604-5DE5257A083CQ36688133-F9F55AAB-4AEB-456D-888D-17A825561420Q36690500-72C5291B-B2EB-46BD-840F-801C2C0D684CQ36695297-0B6F8E8F-825C-47A8-A469-FCAEB196CF85Q36699076-995F97FD-C68E-4609-BA3F-D0253F88E1F4Q36782627-369DC2C1-59EA-419F-8488-C2DCACCE1979Q36793253-26321406-EA76-43D5-82DE-A57875FD3D98Q36806022-CFAEFBDA-7A74-490F-9DF5-6E59844A662BQ36811962-784F450F-9BA1-428D-8381-107F478A5084Q36828367-6E7A7FCB-471F-440B-BBD6-7A9431B822D2Q36829966-0ACADEEF-635B-488E-8B8C-8C2FB7BAB2A9Q36832017-EC8E11DF-F30B-4030-B266-54D2CA70ED72Q37164192-5F64462E-A940-42CB-9334-B9FCC63C7BA7Q37375345-65889245-447C-4891-ACBE-705C38DEBE1BQ37577555-2D4AE789-9521-4DD0-BD3A-1B68FD267571Q37744269-64C63641-8992-4B29-9A02-198E8426EEF7Q37844065-19714DE9-3BCE-4147-A317-40D167B078EAQ37844069-0BCD99E0-95B2-4918-A7DC-7E5386D20042Q40047212-AC0776D1-E27A-48D3-B559-60EA53BA50D3Q40054175-FF8937DB-5056-43B5-B2AD-AF1BCFEDF667Q42939824-C1EBFAFC-19D9-44AF-BD93-45970504A831
P2860
Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120
description
1988 nî lūn-bûn
@nan
1988 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Human immunodeficiency virus t ...... nt envelope glycoprotein gp120
@ast
Human immunodeficiency virus t ...... nt envelope glycoprotein gp120
@en
type
label
Human immunodeficiency virus t ...... nt envelope glycoprotein gp120
@ast
Human immunodeficiency virus t ...... nt envelope glycoprotein gp120
@en
prefLabel
Human immunodeficiency virus t ...... nt envelope glycoprotein gp120
@ast
Human immunodeficiency virus t ...... nt envelope glycoprotein gp120
@en
P2093
P2860
P356
P1476
Human immunodeficiency virus t ...... nt envelope glycoprotein gp120
@en
P2093
C Shimasaki
J E Groopman
P R Clapham
P W Berman
R Ferriani
P2860
P304
P356
10.1073/PNAS.85.14.5200
P407
P577
1988-07-01T00:00:00Z